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Abstract
Background: Patient-reported outcome (PRO) data are integral to patient care, policy decision making and
healthcare delivery. PRO assessment in pressure ulcers is in its infancy, with few studies including PROs as study
outcomes. Further, there are no pressure ulcer PRO instruments available.
Methods: We used gold-standard methods to develop and evaluate a new PRO instrument for people with pressure
ulcers (the PU-QOL instrument). Firstly a conceptual framework was developed forming the basis of PU-QOL scales. Next
an exhaustive item pool was used to produce a draft instrument that was pretested using mixed methods (cognitive
interviews and Rasch Measurement Theory). Finally, we undertook psychometric evaluation in two parts. This first part
was item reduction, using PU-QOL data from 227 patients. The second part was reliability and validity evaluation of the
item-reduced version using both Traditional and Rasch methods, on PU-QOL data from 229 patients.
Results: The final PU-QOL contains 10 scales for measuring symptoms, physical functioning, psychological well-being
and social participation specific to pressure ulcers. It is intended for administration and patients rate the amount of
“bother” attributed during the past week on a 3-point response scale. Scale scores are generated by summing items,
with lower scores indicating better outcome. The PU-QOL instrument was found to be acceptable, reliable (Cronbach’s
alpha values ranging 0.89 - 0.97) and valid (hypothesised correlations between PU-QOL and SF-12 scores (r >0.30) and
PU-QOL scales and sociodemographic variables (r <0.30) were consistent with predictions).
Conclusions: The PU-QOL instrument provides a standardised method for assessing PROs, reflecting the domains in a
pressure ulcer-specific conceptual framework. It is intended for evaluating patient orientated differences between
interventions and in particular the impact from the perspective of patients.
Keywords: Pressure ulcer, Patient-reported outcomes, Health-related quality of life, Reliability, Validity, Rasch analysis,
Rating scale
Background
Chronic wounds are a major health problem and chal-
lenge to patients, healthcare professionals and healthcare
systems. Pressure ulcers (PUs) are chronic wounds that
occur as localised injury to the skin and/or underlying
tissue usually over a bony prominence, as a result of
pressure, or pressure in combination with shear [1]. They
range in size and severity of tissue layer affected, with
particularly vulnerable areas being the sacrum, buttocks
and heels [2]. With widespread prevalence and incidence
in all health settings [3], PUs, often a complication of ser-
ious acute or chronic illness, are a health problem associ-
ated with increased morbidity [4], mortality [5], healthcare
costs and hospitalisation, and identified as a UK National
Health Service (NHS) quality indicator [6].
Both PUs themselves and interventions for preventing
and treating PUs impact health-related quality of life
(HRQL) and can severely compromise all areas of pa-
tient functioning [7,8]. Clinical outcomes associated with
PU prevention or healing, such as incidence or rate of
healing, have been the focus of clinical inquiry; however,
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due to advances in health outcome measurement, such
information alone is no longer sufficient to support pro-
gress being made in the PU field [9]. Cochrane reviews
highlight the lack of robust evidence for the clinical ef-
fectiveness of a majority of PU treatments [10]; resource
availability is not based upon health economic evaluation
and there is no systematic way of considering patients’
priorities for interventions. Therefore, clinical decision
making continues despite being uninformed by high
quality studies based on cost-effectiveness and patients’
perspectives.
The field of health is reliant on health outcome meas-
urement to provide a strong evidence-base, incorporat-
ing both patient perspectives and cost analyses. In health
outcomes research, evaluation of intervention-related
outcomes are often undertaken with the help of rating
scales, or more recently called patient-reported outcome
(PRO) instruments. PRO instruments are increasingly
used in clinical studies for measuring outcome variables.
In this role, instruments are the central dependent vari-
ables which treatment decisions are made. They can be
useful tools for evaluating health changes following in-
terventions if they are fit for purpose and accord with
international standards for rigorous measurement [9,11].
Patient-based outcome measurement in PUs is in its
infancy; few studies have measured PROs and those that
have done, have used generic instruments [12]. A PRO
instrument specific to PUs could help improve the
evidence-base through research assessing effectiveness of
PU therapies; facilitate clinician-patient communication
and shared decision making; prioritise patient problems
and preferences; monitor changes or outcomes of treat-
ment; measure the performance of healthcare providers
and services; and be used in clinical audit [13-15].
Our previous work has identified PROs important to
people with PUs [7,16,17], established the need for a
patient-reported measure of outcomes specific to PUs [12],
and developed a provisional version of such a measure (the
PU-QOL instrument). The PU-QOL instrument was de-
veloped on the basis of a PU-specific HRQL conceptual
framework [16] and existing PU and HRQL literature [7].
These sources provided insight into variables important for
measurement from the perspective of patients with PUs
and were used to generate an exhaustive list of items. The
item list (n=122) was transformed into scales intended to
define coherent clinically meaningful constructs (scales)
consisting of items representing aspects of the continuum
of each construct, reflecting the domains within our
conceptual framework. This produced a preliminary
PU-QOL version which was pre-tested through cognitive
interviews with 35 patients with PUs [18], producing a
provisional PU-QOL version. Pre-testing identified poten-
tial strengths and weaknesses of PU-QOL items, guided
decision-making about modifications to items (content and
response options) and questionnaire design, and provided
early evidence for validity and clinical utility of each PU-
QOL scale as reflected by clinically meaningful hierarchical
scales, prior to formal psychometric evaluation.
The aim of this study was to provide researchers and
clinicians with a comprehensive evaluation of some of
the fundamental psychometric measurement properties
of the provisional PU-QOL instrument.
Methods
We followed international PRO guidelines [9,19-21] for the
development and validation of the PU-QOL instrument
(Figure 1). Collaboration was sought from members of the
European Pressure Ulcer Advisory Panel (EPUAP) and
from 29 acute and primary care NHS organisations around
the UK. A UK NHS Research Ethics Committee provided
ethical approval and all participants gave written informed
consent to participation.
Field test one design
Sample
The first field test was undertaken to construct PU-QOL
scales and perform a preliminary psychometric evaluation
in a large sample of patients with PUs. Patients from acute
and community NHS Trusts around England and Scotland
were included if they were aged ≥18 years, with an existing
PU of any category, location or duration, and able to pro-
vide informed consent to participate. Patients were ex-
cluded if they had only moisture lesions, were unconscious,
confused, cognitively impaired, deemed ethically inappro-
priate to approach, did not speak or understand English or
unable to provide informed consent.
Eligible patients were purposively sampled, ensuring
balanced representation across PU categories (superfi-
cial, severe) and skin sites (torso, limb), setting (acute,
community), age (<70 years, ≥70) and gender. The ‘rule of
thumb’ sample size recommendation for psychometric ana-
lyses of new summated scales is five to 10 subjects per
item, to reduce the effect of chance [19,22]. Following this
recommendation, if the longest potential summated scale
was taken (pain containing 11 items), then a 110 patient
sample would be required. For the Rasch analysis, a sample
of around 250 patients would allow sample selection across
the full measurement range; membership to five class
interval groups of around 50 patients in each group is sug-
gested [23,24].
Rasch analysis
A preliminary psychometric evaluation was performed
using both traditional psychometrics in line with pro-
posed US Food and Drug Administration (FDA) criteria
[9] and new psychometric methods, Rasch Measurement
Theory (RMT) [25]. RMT is increasingly used in the
development of PRO instruments [26,27] as it provides a
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formal method for evaluating scale functioning against a
sophisticated mathematical measurement model, the Rasch
model [25].
A Rasch analysis, using the Andrich Rating Scale
Model [28], was performed using RUMM2030 [29].
The following properties of the provisional PU-QOL
version were examined: mode of administration (patient
self-completed or researcher administered; data will be
published separately), scale targeting, item response cat-
egories, item series (e.g. item-fit) and response bias, to
guide scale construction and identify items with poor psy-
chometric properties for possible elimination. PU-QOL
data was tested against model expectations and any devia-
tions were examined to determine whether scales could be
improved. Final decisions on item inclusion/exclusion were
made according to appraisals of the analyses against
measurement criteria (Table 1) and clinical relevance
(the extent to which items within proposed scales are
clinically cohesive), as opposed to examinations carried out
singularly or sequentially.
Traditional analysis
The 10 Rasch constructed scales underwent a preliminary
psychometric evaluation using traditional psychometric
tests [9,11,22] for: acceptability, scaling assumptions, reli-
ability, and validity. SPSS 15.0 software was used for these
analyses. Psychometric tests and criteria are summarised in
Table 1.
Field test two design
Sample
The second field test was undertaken to perform a com-
prehensive psychometric evaluation of the final (10 scale/
83-item) PU-QOL in a large independent sample of pa-
tients with PUs (eligibility criteria and methods as for field
test 1.1). A sample of around 250 patients would provide
sufficient participants to estimate test-retest reliability;
correlations at levels expected in test-retest situations
(e.g. r >= 0.80) can be estimated with reasonable pre-
cision (95% confidence intervals of ±0.1) with rela-
tively few subjects [46,47].
• Literature review-generated broad HRQL  
domains/important PU-specific PROs identified
• Clinical expert opinion-produced a working conceptual  
framework 
• Qualitative interviews (n=30) with people with PUs - 
revised conceptual framework
• Clinical and methodological expert review = produced a 
conceptual framwork of HRQL outcomes
1.  Construct Defintion - 
PRO development should be 
underpinned by theory (have a 
strong conceptual base) and 
consideration of the target 
population (i.e. people with PUs)
• Literature review of PU and other chronic wound 
measures-no PU instrument available 
• Content from existing instruments did not 
comprehensively represent PU-specific conceptual 
domains
2. Establish need for a new 
measure - 
map content from existing 
instruments to conceptual 
framework
• Qualitative interview transcripts reviewed (30)-patient  
words taken for items
• Operationalisation-content analysed and revised,  
producing 117 items into 13 scales
• Clinical and methodological expert review = produced a 
preliminary instrument
3. Item Generation  
• Semi-structured cognitive interviews with people with 
PUs (n=35)-identified problems with item content  
(ambiguous, confusing), layout and administration
• Revised instrument based on patient recommendations
• Clinical and methodological expert review = produced a 
first draft PU-QOL instrument
4. Pre-testing
• Item analysis and scale construction (n=227)
• Rasch analysis followed by traditional psychometric 
tests for reliability and validity
• Sub-sample (n=75) randomised to self-complete or 
administered groups and differential item functioning 
performed to determine the best administration mode 
for this population
• Clinical and methodological expert review-considered  
analyses in combination and clinical relevance- 
modified first draft PU-QOL
5a. Field Test 1- 
5b. Mode of Administration 
Study
• Final psychometric analysis (n=229)
• Rasch analysis followed by traditional psychometric 
tests for reliability and validity
• Clinical and methodological expert review = produced 
final version PU-QOL
6. Field Test 2
Figure 1 Steps towards developing and evaluating the PU-QOL instrument.
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Table 1 Psychometric tests and criteria used in the evaluation of the PU-QOL instrument
Psychometric property Traditional methods - test and criteria Rasch methods - test and criteria
Acceptability and data quality - Completeness
of item- and scale-level data.
● Score distributions (floor/ceiling effects and
skew of scale scores)
● Even distribution of endorsement frequencies
across response categories (>80%)
● % of item-level missing data (<10%) [30] ● Low number of persons at extreme (i.e. floor/
ceiling) ends of the measurement continuum
● % of computable scale scores (>50%
completed items) [31]
● Items in scales rated ‘not relevant’ <35%
Scaling assumptions - Legitimacy of summing
a set of items (items should measure a common
underlying construct).
● Similar item mean scores [32] and SDs [33] ● Positive residual r between items (<0.30)
● Items have adequate corrected ITC (ITC ≥0.3)
[34]
● High negative residual r (>0.60) suggests
redundancy
● Items have similar ITCs [34] ● Items sharing common variance suggests
uni-dimensionality
● Items do not measure at the same point
on the scale ● Evenly spaced items spanning whole
measurement range
Item response categories - categories in a
logical hierarchy.
● NA ● Ordered set of response thresholds for each
scale item
Targeting - extent to which the range of the
variable measured by the scale matches the
range of that variable in the study sample.
● Scale scores spanning entire scale range ● Person-item threshold distribution: person
locations should be covered by items and
item locations covered by persons when both
calibrated on the same metric scale [35]
● Floor and ceiling (proportion sample at
minimum and maximum scale score) effects
should be low (<15%) [36]
● Skewness statistics should range from −1
to +1 [37]
● Good targeting demonstrated by the mean
location of items and persons around zero
● No published criteria for item level targeting
Reliability
Internal consistency - extent to which items
comprising a scale measure the same
construct (e.g. homogeneity of the scale).
● Cronbach's alphas for summary scores
(adequate scale internal consistency is ≥0.70 [22]
● High person separation index >0.7 [38];
quantifies how reliably person measurements
are separated by items
● Item-total r between +0.4 and +0.6 indicate
items are moderately correlated with scale
scores; higher values indicate well correlated
items with scale scores [22]
● Power-of-tests indicate the power in detecting
the extent to which the data do not fit the
model [24]
● Items with ordered thresholds
*Test-retest reliability - stability of a measuring
instrument.
● Intra-class r coefficient >0.70 between test
and retest scores [11]
● Statistical stability across time points (no uniform
or non-uniform item DIF (p=>0.05 or Bonferroni
adjusted value))
● Pearson r: >0.7 indicates reliable scale stability
Validity ● Involves accumulating evidence from
different forms
Content validity - extent to which the content
(items) of a scale is representative of the
conceptual construct it is intended to measure.
● Consideration of item sufficiency and the
target population
● Clearly defined construct
● Qualitative evidence from individuals for
whom the measure is targeted, expert opinion
and literature review (e.g. theoretical and/or
conceptual definitions) [9].
● Validity comes from careful item construction
and consideration of what each item is meant
to measure, then testing against model
expectations
Construct validity
i) Within-scale analyses - extent to which a
distinct construct is being measured and that
items can be combined to form a scale score.
● Cronbach alpha for scale scores >0.70 ● Fit residuals (item-person interaction) within
given range +/−2.5
● ITC >0.30
● Homogeneity coefficient (IIC mean and
range >0.3)
● Non-significant chi square (item-trait interaction)
values
● Scaling success ● No under- or over-discriminating ICC
● Mean fit residual close to 0.0; SD approaching
1.0 [39]
● Person fit residuals within given range +/−2.5
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Rasch analysis
A Rasch analysis was performed on all 10 PU-QOL scales.
In addition to the properties examined in for field test 1,
differential item functioning (DIF) was also assessed. DIF
occurs when people from different groups (e.g. gender)
with the same latent trait (e.g. pain) have a different prob-
ability of giving a certain response to an item [44]. Groups
to be studied were selected based on theoretical consider-
ations about whether or not the construct measured by
each PU-QOL scale was hypothesised to have the same
conceptual meaning across groups.
Traditional analysis
The final PU-QOL version underwent traditional psy-
chometric analyses as described in for field test 1.
Additional tests for reliability (test re-test) and validity,
including both within- and between-scales testing (con-
vergent, discriminant, known groups) were undertaken
(Table 1). To minimise respondent burden, the SF-12v2
Acute, English (UK) version was used [48] to examine
convergent validity.
Results
Field-test one: scale construction and preliminary
psychometric evaluation
Sample
The first field test screened 989 patients from 21
hospitals, 10 community services and one hospice. Of
those screened, eligibility was assessed for 787 (79.6%);
416 were considered eligible (52.9%); and of those eli-
gible, 287 (69.0%) consented to participate; however, 60
were excluded from analysis as they self-completed the
Table 1 Psychometric tests and criteria used in the evaluation of the PU-QOL instrument (Continued)
Measurement continuum - extent to which
scale items mark out the construct as a
continuum on which people can be measured.
● NA ● Individual scale items located across a
continuum in the same way locations of
people are spread across the continuum [26]
● Items spread evenly over a reasonable
measurement range [40,41]. Items with similar
locations may indicate item redundancy
Response dependency –response to one
item determines response to another.
● NA ● Response dependency is indicated by residual
r >0.3 for pairs of items [40,41]
ii) Between scale analysis
Criterion Validity - hypotheses based on
criterion or ‘gold standard’ measure.
● There are no true gold standard HRQL [42],
PU-specific or chronic wound-specific
measures available [12]
● NA
*Convergent validity - scale correlated with
other measures of the same/ similar constructs.
● Moderate to high r predicted for similar
scales; criteria used as guides to the
magnitude of r, as opposed to pass/fail
benchmarks (high r >0.7; moderate
r=0.3-0.7; low r <0.3) [43]
● NA
*Discriminant validity – scale not correlated
with measures of different constructs
● Low r (<0.3) predicted between scale scores
and measures of different constructs
(e.g. age, gender)
● NA
*Known groups differences - ability of a
scale to differentiate known groups
● ^Generate hypotheses (based on subgroups
known to differ on construct measured) and
compare mean scores (e.g. predict a stepwise
change in PU-QOL scale scores across 3 PU
severity groups and that mean scores would
be significantly different)
● Hypothesis testing (e.g. clinical questions are
formulated and the empirical testing comes
from whether or not data fit the Rasch model)
● Statistically significant differences in mean
scores (ANOVA)
*Differential item functioning (item bias) -
The extent of any conditional relationships
between item response and group membership.
● NA ● Persons with similar ability should respond in
similar ways to individual items regardless of
group membership (e.g. age) [44]
● Uniform DIF - uniformity amongst differences
between groups
● Non-Uniform DIF - non-uniformity amongst
differences between groups; can be considered
at 1% (Bonferroni adjusted) and 5% CIs
Table adapted from [35,45]; *Additional tests performed for field test two; ^The PU HRQL literature is not well established, therefore was limited for identifying
clinical parameters to formulate known groups; NA No test for particular psychometric property; SD Standard deviation; ITC Item total correlation; IIT Inter-item
correlation; ICC Item characteristic curve; r correlation; ANOVA, Analysis of variance; DIF Differential item functioning; CI Confidence interval.
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PU-QOL (data on the self-completed sample will be
published elsewhere). Cognitive impairment was the
main reason for ineligibility (38.8%). Table 2 presents the
sample characteristics.
Rasch analysis: item reduction and scale formation
The first psychometric evaluation produced a 10-scale
instrument (Table 3). The Rasch analysis detected im-
portant limitations of the PU-QOL scales, resulting in
modifications. It detected that the four-category item
scoring function did not work as intended for multiple
items. For those items where the response categories
were working as intended, thresholds were close to being
disordered; people had difficulty distinguishing between
‘a little bother’ and ‘quite a bit of bother’ categories. This
provided good evidence that items would benefit from
fewer response categories. All scale items were subjected
to a post hoc rescoring by collapsing adjacent categories.
Re-analysis demonstrated that all thresholds were now
correctly ordered, producing scales with three categories
(0 = no bother, 1 = little bother, 2 = a lot of bother).
Targeting between the distribution of person mea-
surements and item locations indicated that the sam-
ples were adequate for examining the scales but the
scales were suboptimal for measuring the sample. Sig-
nificant ceiling effects indicated that scales might pro-
vide limited information about people at the extremes
of the sample distribution (those with least disability/
impairment). However, the location ordering of scale
items was clinically sensible, providing evidence towards
construct validity. Some items had notable criterion fail-
ures: fit residuals outside +/−2.5; high chi-squared values
with significant p-value, and significantly under- or over-
discriminating item characteristic curves (Table 3). Few
items exceeded +/−0.3 residual correlations, indicating that
item responses are independent of each other and no re-
dundant items. Departures from item fit expectation were
considered in combination and guided item removal. Per-
son separation index values indicated good to reasonable
reliability for scales distinguishing between responders on
each scale variable (Table 3).
Traditional analysis
A preliminary psychometric evaluation against traditional
psychometric criteria supported the PU-QOL scales as reli-
able and valid measures of PU-symptoms, physical and
social functioning, and psychological well-being. Briefly,
data quality was high (scale scores were computable for
93–99.6% of respondents) and scaling assumptions were
satisfied (similar mean item scores, corrected item-total
correlations ranged 0.53-0.92). Scale-to-sample targeting
was good (scale scores spanned the scale range but were
notably skewed for three scales (values outside +/−1.0),
mean scores were near scale mid-points for 67% of scales,
Table 2 Participant characteristics
Field test 1 Field test 2
Characteristics Range (Mean, SD) Range (Mean, SD)
Age 24 - 98 (72, 13.5) 20 - 103 (71.3, 16.5)
Gender Total n (%) Total n (%)
Total n=227 n=229
Male 90 (39.6) 119 (52.0)
Female 137 (60.4) 110 (48.0)
Ethnicity
White 223 (98.2) 227 (99.1)
Asian 1 (0.4) 2 (0.9)
Black/African 2 (0.4) 0
Chinese 0 0
Not stated 1 (0.4) 0
Setting
Hospital (surgery) 99 (43.6) 62 (27.1)
Hospital (medicine) 21 (9.3) 74 (32.3)
Community 107 (47.1) 88 (38.4)
PU severity
Category 1 38 (10.6%) 76 (18.1%)
Category 2 144 (40.2%) 170 (40.5%)
Category 3/4 153 (42.7%) 170 (40.5%)
Missing 1 (0.3%) 4 (0.9%)
PU risk classification
Short-term risk 39 (17.2) 36 (15.7)
Medium to long-term risk 71 (31.3) 87 (38.0)
On-going long-term risk 116 (51.1) 103 (45.0)
Missing 1 (0.4) 3 (1.3)
Marital status
Single 59 (26.0) 71 (31.0)
Married 85 (37.5) 77 (33.6)
Cohabiting 81 (35.7) 75 (32.8)
Missing 2 (0.8) 6 (2.6)
Living arrangements
Live alone 84 (37.0) 86 (37.6)
Cohabit with carer 63 (27.8) 51 (22.3)
Cohabit with other 61 (26.9) 48 (20.9)
Missing 19 (8.4) 44 (19.2)
Education
No formal education 129 (56.8) 125 (54.6)
GCSE or equivalent 39 (17.2) 40 (17.5)
A-Level or equivalent 25 (11.0) 16 (6.9)
Degree or higher 15 (6.6) 21 (9.2)
Missing 19 (8.4) 27 (11.8)
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and ceiling effects were negligible; however floor effects
exceeded the 15% criterion for two scales. Reliability was
high as demonstrated by Cronbach’s alpha values (range
0.89-0.96; Table 3). The item-total correlations, alpha coef-
ficient and homogeneity coefficient (inter-item correlation
mean and range; Table 3) provide evidence towards the in-
ternal construct validity of PU-QOL scales.
Field-test two: final psychometric evaluation
Sample
The second field test involved a comprehensive psycho-
metric evaluation of the final (10 scale/83-item) PU-QOL,
using RMT and traditional psychometric methods. A total
of 879 patients were screened of whom eligibility was
assessed for 717 (81.6%); 391 were considered eligible
(54.5%); and of those eligible, 231 (59.1%) consented to
participate; however two were excluded from analysis (one
patient died; one patient was recruited twice). Table 2 pre-
sents the sample characteristics.
Rasch analysis
The measurement properties of PU-QOL scales were
largely supported as demonstrated through items that
mapped out continua of increasing intensity and located
items along those continua in a clinically sensible order.
Scale items work together to define single variables, al-
beit, some item misfit and local dependence (Table 4).
DIF was demonstrated in three items (e.g. items ‘diffi-
culty standing for long periods’ and ‘limited in ability to
go up and down stairs’ from the mobility scale; Table 4),
however deviations from model expectations were mar-
ginal, suggesting item performance across the four clin-
ical subgroups is stable and that these groups can be
measured on a common ruler.
Table 3 Summary of preliminary PU-QOL instrument psychometric analysis, field test 1
Scale (No. of items) Rasch analysis Traditional psychometric analysis
Items with
disordered
thresholds
Item
locations
logits range
Fit statistics
fit residuals
outside +/−2.5
Items with Chi
square probability
significance ≥0.001
Person
separation
index
Cronbach
alpha
Range IIC Scaling
assumptions
corrected ITC
Pain (8) 5 -0.94 − 0.80 0 4 0.78 0.89 0.24 – 0.66 0.53 – 0.70^
Exudate (8) 4 -0.51 − 0.48 0 0 0.59 0.92 0.40 – 0.86 0.56 – 0.84^
Odour (6) 2 -1.47 − 0.60 0 0 0.62 0.96 0.74 – 0.91 0.83 – 0.92^
Sleep (6) 3 -0.54 − 0.31 0 0 0.62 0.92 0.48 – 0.84 0.67 – 0.86^
Vitality (3) 0 -0.48 − 0.44 0 0 0.03 n/a n/a n/a
Movement/mobility (11) 4 -0.33 − 0.48 0 0 0.58 0.93 0.23 – 0.91 0.67 – 0.80^
ADL (9) 8 -0.54 − 0.57 0 0 0.29 0.95 0.41 – 0.90 0.58 – 0.90^
Emotional well-being (17) 4 -1.15 − 1.46 1 0 0.82 0.93 0.24 – 0.79 0.54 – 0.76^
Appearance & self-
consciousness (7)
4 -0.83 − 0.65 0 0 0.56 0.90 0.41 – 0.75 0.60 – 0.79^
Participation (9) 4 -0.56 − 0.54 0 0 0.65 0.96 0.53 – 0.89 0.73 – 0.90^
IIC inter-item correlation; ^Range item-total correlation (ITC).
Table 4 Summary of PU-QOL Rasch analysis, field test 2
Scale (No. of items) Disordered
thresholds
Item locations
logits range
Fit statistics
fit residuals
outside +/−2.5
Items with Chi
square probability
significance ≥0.001
Person
separation
index
DIF age DIF gender DIF HC setting
Uni Non Uni Non Uni Non
Pain (8) 0 -1.11 − 1.03 0 0 0.72 0 0 0 0 0 0
Exudate (8) 1 -0.75 – 0.84 1 1 0.69 0 0 0 0 0 0
Odour (6) 0 -1.31 – 0.91 0 0 0.66 0 0 0 0 0 0
Sleep (6) 0 -0.91 – 0.45 1 1 0.62 0 0 0 0 0 0
Mobility and movement (9) 2 -0.46 – 0.57 0 0 0.42 0 0 0 0 2 0
Activity (8) 4 -0.30 – 0.56 0 0 0.27 0 0 0 0 0 0
Vitality (6) 0 -0.50 – 0.81 0 0 0.38 1 0 0 0 0 0
Emotional well-being (15) 2 -1.48 – 2.44 0 0 0.86 0 0 0 0 0 0
Self-consciousness (7) 0 -1.27 – 1.02 0 0 0.58 0 0 0 0 0 0
Participation (9) 7 -0.91 – 1.00 0 0 0.57 0 0 0 0 0 0
DIF differential item functioning; HC healthcare; Uni uniform DIF; Non non-uniform DIF.
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The Rasch analysis detected some important limita-
tions; the three-category scoring function did not work
as intended for some scale items, indicated by disor-
dered thresholds (e.g. items ‘walking slowed’ and ‘lim-
ited in ability to walk’ from the mobility scale; items
‘regular activities’ and ‘jobs around the house’ from the
activity scale), and targeting problems emerged. Inspec-
tion of threshold distributions demonstrated sub-optimal
targeting of PU-QOL scales to the study sample for most
scales (items did not span the full range of the patient
sample, indicating that measurement could be improved
at the extreme ends of some scales; Table 4. The largest
frequency of respondents was often at the ceiling of scale
ranges (least bother). Ideally, there should be a good
match between the scale and sample ranges, with people
falling within the range of the items. As sample sizes
were small for some scales (e.g. removing people with no
odour bother resulted in a sample of 27 for analysis), it
was deemed premature to make major modifications to
items and the scoring function without additional empir-
ical evidence.
Traditional analysis
The traditional psychometric evaluation supported the
PU-QOL scales as reliable and valid measures of PU-
symptoms, physical and social functioning, and psycho-
logical well-being. Total scores could be computed for
most people (computable scale scores ranged 95.6-99.6%),
implying good data quality. Scaling assumptions were satis-
fied (corrected item-total correlations ranged 0.51-0.94).
All item-own-scale correlations were high (corrected item-
total correlations ranged 0.525-0.920; Table 5) and satisfied
recommended criteria (> 0.3), thus providing support that
items within scales measured a common underlying con-
struct. Corrected item-total correlation >0.3 indicated that
items within scales contained a similar proportion of infor-
mation. Scale-to-sample targeting was reasonable: scale
scores spanned the scale ranges but were notably skewed
for exudate odour and self-consciousness scales (value out-
side +/−1.0); mean scores were near scale mid-points for
only pain, sleep and mobility scales, however due to many
people responding at the floor (lowest score), this finding
is expected; and ceiling effects were negligible, however
floor effects exceeded the 15% criterion for exudate, odour,
vitality, and appearance and self-consciousness scales.
Reliability was high as demonstrated by Cronbach’s
alpha values for all PU-QOL scales exceeding the stand-
ard criterion of 0.7 (Table 5). Item–total correlations
ranged 0.525-0.920, fulfilling the recommended criteria
(>0.3). Test-retest correlations for 8/10 scales exceeded
0.7; two scales had correlations below the recommended
criteria, but marginally (Table 5), thus mostly fulfilling
the recommended minimum criteria and indicating good
scale stability.
Evidence of internal construct validity was supported by
moderate to high item-total correlations; high Cronbach’s
coefficient alphas; and moderate to high inter-item correla-
tions (means >0.48; ranges 0.226-0.934; Table 5), indicating
that each PU-QOL scale measures a single construct.
Hypothesised correlations between PU-QOL and related
SF-12 scales were consistent with predictions (Table 5),
thus providing support that scales measure what they in-
tend to measure; moderate to high correlations (r >0.30)
were predicted. Correlations between PU-QOL scales and
sociodemographic variables (age, gender) were consistent
with predictions (r <0.30; Table 5), suggesting responses to
scales are not biased by age or gender. Hypothesised group
differences were as predicted for scales: exudate, odour,
vitality, daily activities, emotional well-being, and self-
consciousness, with significant step increases in mean
scores observed by PU severity groups. In contrast, there
was no step increase in mean scores for scales: pain, sleep,
mobility and movement, and participation. Apart from the
sleep scale, the mean score on outcomes for category 1 PU
severity was lower than category 3/4 severity, suggesting
that HRQL outcomes are worse for people with severe PUs
compared to those with superficial category 1 PUs. It is im-
portant to note that category 1 PUs had small samples
(range 4–14 patients) therefore known groups results are
considered preliminary.
Final PU-QOL Instrument
The final PU-QOL is a self-report instrument, comprising
of 10 scales. These include three symptom (pain (8 items),
exudate (8 items), odour (6 items)), plus an itchiness item;
four physical functioning (sleep (6 items), movement
and mobility (9 items), daily activities (8 items), vitality
(5 items)); two psychological well-being (emotional
well-being (15 items), self-consciousness and appearance
(7 items)); and one social participation scale (9 items). It
is intended for administration where patients rate the
amount of “bother” attributed (e.g. “During the past week,
how much have you been bothered by…?”) on a 3-point re-
sponse scale (e.g. 0=not at all - 2=a lot). Scale scores are
generated by summing items and then transforming to a
0–100 scale. High scores indicate greater patient bother.
Discussion
The PU field requires a strong evidence-base that incor-
porates health outcome measurement from the patient
perspective. To fully capture and quantify the patients’
viewpoint, appropriately constructed and validated in-
struments are required. The PU-QOL instrument con-
sists of 10 scales for measuring symptoms and physical,
psychological, and social functioning specific to PUs.
This is the first outcome measure reflecting PU-specific
conceptual HRQL domains; content that differs from other
chronic wound-specific instruments [12], and provides a
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Table 5 Summary of PU-QOL traditional psychometric analysis, field test 2
Scale (No. of items) Internal consistency
Cronbach’s alpha
IIC Scaling assumptions-
corrected ITC
Test retest reproducibility Convergent validity Discriminant validity
ICC consistency ICC absolute Correlation Related SF12
scale r1
PU-QOL HRQL
item r1 (n)
Gender R2 (n) Age r2 (n)
Pain (8) 0.89 0.24 – 0.66^ 0.53 – 0.70^ 0.80 0.81 0.80 0.48b 0.38b (206) 0.13b (214) 0.11b (214)
Exudate (8) 0.91 0.32 – 0.72^ 0.51 – 0.75^ 0.62 0.63 0.62 n/a 0.25a (216) 0.08b (225) -0.14b (224)
Odour (6) 0.97 0.72 – 0.93^ 0.79 – 0.94^ 0.68 0.68 0.70 n/a 0.20a (217) 0.05b (228) -0.14b (227)
Sleep (6) 0.92 0.49 – 0.81^ 0.68 – 0.85^ 0.82 0.82 0.82 n/a 0.32b (171) 0.21b (178) 0.10b (178)
Vitality (6) 0.90 0.49 – 0.90^ 0.63 – 0.90^ 0.74 0.74 0.74 0.36b 0.52b (135) 0.03b (137) -0.16b (137)
Movement/Mobility (9) 0.93 0.23 – 0.91^ 0.67 – 0.80^ 0.87 0.86 0.88 -0.50b 0.39b (37) 0.04b (39) 0.22b (39)
ADL (8) 0.95 0.41 – 0.90^ 0.58 – 0.90^ 0.87 0.87 0.87 -0.38b 0.35b (48) -0.05b (49) -0.19b (49)
Emotional well-being (15) 0.94 0.24 – 0.79^ 0.54 – 0.76^ 0.83 0.82 0.83 -0.44b 0.58b (133) 0.16b (135) -0.15b (135)
Appearance &
self-consciousness (7)
0.89 0.37 – 0.79^ 0.62 – 0.76^ 0.81 0.81 0.81 -0.40b 0.50b (176) 0.23b (179) -0.03b (178)
Participation (9) 0.93 0.36 – 0.88^ 0.60 – 0.86^ 0.63 0.64 0.63 -0.52b 0.51b (75) 0.01b (76) -0.29b (76)
IIC inter-item correlation; ^Range item-total correlation (ITC); 1Spearman correlation; 2Pearson correlation; aCorrelations falling outside of the predicted range; bCorrelations consistent with predictions.
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framework for designing future research that consequently
improves the quality of research in the field by inclusion of
PU-specific PROs.
Scale development and item reduction were primarily
guided by RMT. RMT provides a powerful framework to
guide scale construction by detecting items deviating from
model expectations with the intention of improving scale
attributes. Evidence from RMT was used to understand
why some scale items were not working and to pin point
where improvements could be made. However, final deci-
sions on item inclusion were made according to appraisals
of the analyses of the observed data against measurement
criteria and clinical relevance, as opposed to examinations
carried out singularly or sequentially.
The final psychometric evaluation demonstrated that
PU-QOL scales mostly satisfy criteria for acceptability,
reliability and validity, in line with recommended FDA
guidelines for measurement [9]. However, the Rasch
analysis detected targeting problems despite attempts to
sample a wide variety of patients with PUs drawn across
settings. Targeting is justified for the exudate and odour
scales as not all patients have these problems; it is clinic-
ally reasonable that these people fall outside the scale
range. Importantly, where people have symptom bother,
there needs to be items within the scales that discrimin-
ate symptom bother, and in this instance, the symptom
scales perform this function. For the remaining scales,
targeting could be improved by developing items that
span a wider measurement range, and in the process,
maximise the potential of the PU-QOL to detect change.
Extending the measurement range can be achieved with-
out affecting the scales as they stand, because the item
locations are calibrated relative to each other. Important
to note, scale scores for >65% of the samples were within
the best performing part of all scales. For example, the
pain scale items spread 2-logits compared to a person
spread of 7 logits, indicating suboptimal targeting. But
for the majority of people in the sample, the measure-
ment range distribution was within the range where
most people lay, indicating good pain scale performance.
Given the heterogeneity of the population with PUs,
further work is required to ensure that the PU-QOL
scales fit the needs of all people with PUs including
patients with superficial PUs. Appropriateness of PU-QOL’s
use in individual decision-making needs investigation;
strengthening the measurement precision could improve
the PU-QOLs ability to detect differences in HRQL out-
comes between people with different PU severity. This
is important for making inferences from future research
using the PU-QOL. However, one consideration is that
during field testing, as is standard practice, patients re-
ceived some form of treatment for their PU; information
that was not collected (e.g. amount of analgesia). There-
fore, the true impact of PUs may not have been captured
(lower severity represented in the sample due to treatment
effect) and be the reason for, at least in part, mistargeting
and misrepresentation of known groups testing. In
actual fact, PUs appear to cause patients more bother
(as indicated from the qualitative work) than was repre-
sented but good care received lowered PU impact in the
sample. This is a methodological issue in this area. Finally,
the three-category scoring function did not work as
intended for some scale items and requires exploration.
The above limitations do not preclude use of the PU-QOL
instrument. PU-QOL scales can be included as one out-
come measure, amongst others, for group comparisons in
future PU research (e.g. clinical trials) on the proviso that
studies have built in a parallel psychometric analysis to
indicate the performance (psychometric evaluation) of the
scales in future samples.
The final Rasch analyses provides an initial evidence-
base for future testing to improve the PU-QOL scales
and to establish the extent that psychometrically sound
scales have been developed. Future scale developments
can be empirically driven; the distribution of item loca-
tions highlight where ‘gaps’ in the measurement con-
tinuum are (fill notable distances in item locations with
items, particularly those representing superficial PU im-
pact and extend the measurement range at the extreme
ends of the continuum). The process of modifying a
newly developed instrument is part of an evolving, on-
going measurement process intended to strengthen the
hypothesised conceptual relationships with empiric evi-
dence [49]. The usefulness of new measures is therefore
demonstrated by multiple applications in different stud-
ies (accumulative body of evidence to support scale
measurement properties). Future research will investi-
gate the sensitivity of PU-QOL scales to change and
responsiveness, and develop an instrument to enable eco-
nomic evaluation. Development of proxy measures and
language translations are needed given the high prevalence
of cognitively impaired patients with PUs.
The PU-QOL instrument is intended for administra-
tion, following a user manual, with adults across the
range of PU severity and type (location and duration)
and UK acute and community healthcare settings. Scales
can be selected depending on the nature of the research
and scale items are summed to produce scores. The PU-
QOL can be used for: effectiveness intervention research
where improvement and/or deterioration in HRQL is
measured; promoting patient-clinician communication
(i.e. flag issues); informing changes to treatment; facili-
tating priority setting and patient care and PU manage-
ment decisions and assessing the care given from the
patient’s perspective. Currently, the PUQOL is most ap-
propriate for people with severe PUs, as demonstrated
by a lack of items to represent people with little or no
bother due to PUs. The exudate and odour scales are
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not intended for people with superficial category 1 PUs.
Electronically defined ‘skip’ questions would assist in
selecting scales and items relevant to each individual’s
circumstance.
As the PU-QOL was developed and evaluated in the
UK, the validity and reliability are characteristics of the
instrument for a specific population (i.e. UK nationals)
and should therefore be re-evaluated for a new popula-
tion. A language translation or cross-cultural adaption
may be required to ensure that the PU-QOL is appropri-
ate for cultures, languages and ethnic groups outside the
UK (see the PU-QOL instrument website for guidance
on language translation and cross-cultural adaptation
processes: http://ctru.leeds.ac.uk/Skin).
This research highlights the importance of fully testing
instruments before clinicians and researchers apply
them. It highlights the value of item-level analyses, not
typically undertaken, that identified problems with the
PU-QOL scales not detected by standard tests of scale
reliability and validity. It also demonstrated that small it-
erative steps, using mixed methods in an interactive way,
rather than the traditional three stage approach to PRO
development (i.e. qualitative work to generate constructs
and content, pre-testing and psychometric evaluation)
may be beneficial, particularly at early content and scale
format/design to understand and resolve instrument is-
sues early in the development process. Both qualitative
and empirical findings should be used to inform subse-
quent work and to make improvements to scales. Uni-
formity of research approaches for PRO development
could lead to consistency in health measurement and the
inclusion of mixed methods as well as the more sophisti-
cated psychometric methods, such as RMT in accepted
international guidelines.
Conclusions
This study makes important contributions to the PU and
wider health measurement fields. The findings demon-
strate that mixed methods, including RMT were benefi-
cial for developing a new PRO instrument specific for
PUs; a methodology that can be applied for further
development of the PU-QOL as well as PROs in other
health areas. The PU-QOL instrument provides a means
for the comprehensive assessment of PU impact and
for quantifying the benefits of PU interventions from
the patients perspective; thus far lacking in the area.
A scientifically rigorous PRO measurement needs to
become more commonplace in the PU field so that
the goal of PU management can be to enhance and
maintain the HRQL of people with PUs. Subject to fur-
ther development, PU-QOL is a tool with which to
evaluate whether PU treatments and the healthcare
given achieve this; outcomes that are ultimately best
judged by patients themselves.
Competing interests
The authors declare they have no completing interests.
Authors’ contributions
CG contributed to study concept and design, acquisition of study data,
analysis and interpretation of results, and preparation of the final manuscript.
JB contributed to study design, interpretation of results and preparation of
the final manuscript. SC contributed to study design, psychometric analysis,
interpretation of data, and preparation of the final manuscript. DL contributed
to study design, interpretation of data and provided methodological
expertise. MB, SCo, CD, EM, EAN, NS and LW contributed to interpretation of
results and preparation of the final manuscript, and provided clinical expertise
throughout the duration of the study. JN contributed to study concept and
design, interpretation of results and preparation of the final manuscript. All
authors read and approved the final manuscript.
Acknowledgments
This paper presents independent research funded by the National Institute
for Health Research (NIHR) under its Programme Grants for Applied Research
programme (RP-PG-0407-10056). The views expressed in this paper are those
of the author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health. We appreciate the help of all research teams at
participating centres around England and Scotland and the participants for
taking time to be involved in this research. We thank the health outcome
methodologists Professor Katerina Hilari, and Drs Sarah Smith, Sarah Schroter,
Yasmene Alavi, and Jennifer Petrillo for reviewing the item pool and the
draft, preliminary and final versions of the PU-QOL. The PU-QOL instrument
is available to clinicians and researchers at http://ctru.leeds.ac.uk/Skin.
Practical information necessary for administration and scoring can be found
in a user’s manual. The manual includes information about the purposes for
which the PU-QOL instrument should and should not be used.
Author details
1Clinical Trials Research Unit (CTRU), University of Leeds, Leeds LS2 9JT, UK.
2Clinical Neurology Research Group, Peninsula College of Medicine and
Dentistry, Plymouth, UK. 3Department of Health Services Research and
Teaching, London School of Hygiene & Tropical Medicine, London, UK.
4School of Healthcare, University of Leeds, Leeds, UK. 5University Hospital
Birmingham NHS Foundation Trust, Birmingham, UK. 6Tissue Viability Service,
Leeds Teaching Hospitals NHS Trust, Leeds, UK. 7Leeds Community
Healthcare NHS Trust, Leeds, UK.
Received: 13 December 2012 Accepted: 5 April 2013
Published: 13 June 2013
References
1. National Pressure Ulcer Advisory Panel and the European Pressure Ulcer
Advisory Panel (NPUAP/EPUAP): Prevention and Treatment of Pressure Ulcers:
Clinical Practice Guideline. Washington CD: NPUAP; 2009:16–20.
2. Bridel J: The epidemiology of pressure sores. Nurs Stand 1993, 7:25–30.
3. Kaltenthaler E, Whitfield MD, Walters SJ, Akehurst RL, Paisley S: UK, USA and
Canada: how do their pressure ulcer prevalence and incidence data
compare? J Wound Care 2001, 10:530–535.
4. Thomas DR, Goode PS, Tarquine PH, Allman RM: Hospital-acquired
pressure ulcers and risk of death. J Am Geriatr Soc 1996, 44:1435–1440.
5. Allman RM, Goode PS, Patrick MM, Burst N, Bartolucci AA: Pressure ulcer
risk factors among hospitalized patients with activity limitation. JAMA
1995, 273:865–870.
6. NHS: NHS Safety Thermometer. 2012. http://www.ic.nhs.uk/services/nhs-
safety-thermometer.
7. Gorecki C, Brown J, Nelson E, Briggs M, Schoonhoven L, Dealey C, et al:
Impact of pressure ulcers on quality of life in older patients: A
systematic review. J Am Geriatr Soc 2009, 57:1175–1183.
8. Spilsbury K, Nelson A, Cullum N, Iglesias C, Nixon J, Mason S: Pressure
ulcers and their treatment and effects on quality of life: hospital
inpatient perspectives. J Adv Nurs 2007, 57:494–504.
9. US Department of Health & Human Services FDA: Patient reported outcome
measures: Use in medical product development to support labelling claims.
MD: S Department of Health & Human Support Food & Drug
Administration; 2009.
Gorecki et al. Health and Quality of Life Outcomes 2013, 11:95 Page 11 of 12
http://www.hqlo.com/content/11/1/95
10. The Cochrane Collaboration: The Cochrane Library. 2009. http://www.
thecochranelibrary.com/view/0/index.html.
11. Scientific Advisory Committee of the Medical Outcomes Trust: Assessing
health status and quality-of-life instruments: attributes and review
criteria. Qual Res 2002, 11:193–205.
12. Gorecki C, Nixon J, Lamping DL, Alavi Y, Brown JM: Patient-reported
outcome measures for chronic wounds with particular reference to
pressure ulcer research: A systematic review. Int J Nurs Stud 2013,
doi:10.1016/j.ijnurstu.2013.03.004.
13. Browne J, Jamieson L, Lawsey J, van der Meulen J, Black N, Cairns J, et al:
Patient reported outcome measures (PROMs) in elective surgery. Report to the
Department of Health. 2007. Available from: www.lshtm.ac.uk/hsru/research/
PROMs-Report-12-Dec-07.pdf.
14. Greenhalgh J: The applications of PROs in clinical practice: what are they,
do they work, and why? Qual Life Res 2009, 18:115–123.
15. Velikova G, Booth L, Smith A, Brown P, Lynch P, Brown J: Measuring quality
of life in routine oncology practice improves communication and patient
well-being: A randomised controlled trial. J Clin Oncol 2004, 22:714–724.
16. Gorecki C, Lamping DL, Brown JM, Madill A, Firth J, Nixon J: Development
of a conceptual framework of health-related quality of life in pressure
ulcers: a patient-focused approach. Int J Nurs Stud 2010, 47:1525–1534.
17. Gorecki C, Nixon J, Madill A, Firth JJ: What influences the impact of
pressure ulcers on health-related qualityof life? A qualitative patient-
focused exploration of contributory factors. J Tissue Viability 2012, 21:3–12.
18. Gorecki C, Lamping D, Nixon J, Brown J, Cano S: Applying mixed methods
to pretest the Pressure Ulcer Quality of Life (PU-QOL) instrument. Qual
Life Res 2012, 21:441–451.
19. Blazeby J, Sprangers M, Cull A, Groenvold M, Bottomley A, EORTC Quality of
Life Group: Guidelines for Developing Questionnaire Modules. 3rd edition. ; 2002.
20. Rothman M, Burke L, Erickson P, Kline Leidy N, Patrick D, Petrie C: Use of
existing patient-reported outcome (PRO) instruments and their modification:
The ISPOR good research practices for evaluating and documenting content
validity for the use of existing instruments and their modification PRO tasck
force report. Value Health 2009, 12:1075–1083.
21. Streiner D, Norman G: Health Measurement Scales: A Practical Guide to Their
Development and Use. 3rd edition. Oxford: Oxford University Press; 2003.
22. Nunnally J, Bernstein I: Psychometric Theory. 3rd edition. New York: McGraw-
Hill; 1994.
23. Andrich D: Rasch models for measurement. Beverly Hills: Sage Publications; 1988.
24. Andrich D, Luo G, Sheridan B: Interpreting RUMM2020. Perth, WA: RUMM
Laboratory; 2004.
25. Rasch G: Probabilistic models for some intelligence and attainment tests.
Chicago: University of Chicago; 1960.
26. Hobart J, Cano S, Zajicek J, Thompson A: Rating scales as outcome
measures for clinical trials in neurology: problems, solutions, and
recommendations. Lancet Neurol 2007, 6:1094–1095.
27. Tennant A, McKenna S, Hagell P: Application of Rasch Analysis in the
Development and Application of Quality of Life Instruments. Value Health
2004, 7:S22–S26.
28. Andrich D: Rating formulation for ordered response categories.
Psychometrika 1978, 43:561–573.
29. Andrich D, Sheridan B, Luo G: RUMM 2030. 4.0 for windows (upgrade
4600.0109. 2010. Perth, WA, RUMM Laboratory PTY LTD. Perth, WA: RUMM
Laboratory; 2010. http://www.rummlab.com.au/.
30. Group WHOQOL: The World Health Organization Quality of Life
Assessment (WHOQOL): development and general psychometric
properties. Soc Sci Med 1998, 46:1569–1585.
31. Ware J, Snow K, Kosinski M, Gandek B: SF-36 Health survey: Manual and
interpretation guide. 2nd edition. Boston, USA: New England Medical
Centre; 1997.
32. Likert R: A technique for the measurement of attitudes. Arch Psychol 1932,
140:5–55.
33. McHorney CA, Ware J, Lu J, Sherbourne C: The MOS 36-Item Short-Form
Health Survey (SF-36): III.Tests of data quality, scaling assumptions and
reliability accross diverse patient groups. Med Care 1994, 32:40–66.
34. Ware J, Harris W, Gandek B, Rogers B, Reese P: MAP-R for windows: multitrait/
multi-item analysis program - revised user's guide. Boston, MA: Health
Assessment lab; 1997.
35. Hobart JC, Cano S: Improving the evaluation of therapeutic interventions
in multiple sclerosis: the role of new psychometric methods. Health
Technol Assess 2009, 12:1.
36. McHorney CA, Tarlov A: Individual-patient monitoring in clinical practice:
are available health status surveys adequate? Qual Life Res 1995, 4:293–307.
37. Hays R, Anderson R, Revicki D: Psychometric consideration in evaluating
health-related quality of life measures. Qual Life Res 1993, 2:441–449.
38. Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, et al:
Evaluating quality-of-life and health status instruments: development of
scientific review criteria. Clin Ther 1996, 18:979–992.
39. Tennant A, Conaghan P: The measurement model model in rheumatology:
What is it and why use it? When should it be applied, and what should one
look for in a Rasch paper? Arthritis Rheum 2007, 57:1358–1362.
40. Hobart J, Riazi A, Thompson A, Styles I, Ingram W, Vickery P, et al: Getting
the measure of spasticity in multiple sclerosis: the Multiple Sclerosis
Spasticity Scale (MSSS-88). Brain 2006, 129:224–234.
41. Wright B, Masters G: Rating scale analysis: Rasch measurement. Chicago:
MESA; 1982.
42. Fayers P, Hays R: Assessing quality of life in clinical trials: Methods and
practice. Oxford: Oxford University Press; 2005.
43. Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas
1960, 20:37–46.
44. Teresi J, Ramirez M, Lai J, Silver S: Occurences and sources of Differential
Item Fuctioning (DIF) in patient-reported outcome measures: Description
of DIF methods, and review of measures of depression, quality of life
and general health. Psychol Sci Q 2008, 50:538.
45. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon, Sagnier PP:
The community-acquired pneumonia symptom questionnaire: a new,
patient-based outcome measure to evaluate symptoms in patients with
community-acquired pneumonia. Chest 2002, 3:920–929.
46. Fleiss J: Reliability of measurements. In The design and analysis of clinical
experiments. New York: John Wiley & Sons; 1986:2–31.
47. Guyatt G, Walter S, Norman G: Measuring change over time:assessing the
usefullness of evaluative instruments. J Chron Disabil 1987, 4:171–178.
48. Ware J, Kosinski M, Turner-Bowker D: How to score version 2 of the SF-12
Health Survey (with a supplement documenting version 1). Lincolm, RI: Quality
Metric Incorporated; 2002.
49. Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B: Patient-
Reported Outcomes: Conceptual Issues. Value Health 2007, 10:S66–S75.
doi:10.1186/1477-7525-11-95
Cite this article as: Gorecki et al.: Development and validation of a new
patient-reported outcome measure for patients with pressure ulcers:
the PU-QOL instrument. Health and Quality of Life Outcomes 2013 11:95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gorecki et al. Health and Quality of Life Outcomes 2013, 11:95 Page 12 of 12
http://www.hqlo.com/content/11/1/95
